Head-To-Head Review: Neurogene (NGNE) vs. Its Peers

Neurogene (NASDAQ:NGNE) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Neurogene to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Insider & Institutional Ownership

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Neurogene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Neurogene Competitors	-9,046.59%	-199.78%	-30.61%

Analyst Recommendations

This is a breakdown of recent ratings for Neurogene and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1	0	5	2	3.00
Neurogene Competitors	9782	15052	45296	1571	2.54

Neurogene currently has a consensus price target of $80.29, indicating a potential upside of 201.03%. As a group, “Biotechnology” companies have a potential upside of 97.59%. Given Neurogene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than its competitors.

Volatility & Risk

Neurogene has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurogene’s competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neurogene and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neurogene	$930,000.00	-$90.35 million	-5.30
Neurogene Competitors	$691.14 million	$10.43 million	-10.02

Neurogene’s competitors have higher revenue and earnings than Neurogene. Neurogene is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Neurogene beats its competitors on 7 of the 12 factors compared.

Neurogene Company Profile

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.